Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes

BACKGROUND: Fewer circulating endothelial progenitor cells (EPCs) and increased plasma (C-term) stromal cell-derived factor 1α (SDF-1α), a substrate of DPP-4, are biomarkers, and perhaps mediators, of cardiovascular risk and mortality. Short-term/acute treatment with DPP-4 inhibitors improve EPC bio...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cardiovasc Diabetol
Autori principali: Dei Cas, Alessandra, Spigoni, Valentina, Cito, Monia, Aldigeri, Raffaella, Ridolfi, Valentina, Marchesi, Elisabetta, Marina, Michela, Derlindati, Eleonora, Aloe, Rosalia, Bonadonna, Riccardo C., Zavaroni, Ivana
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5324295/
https://ncbi.nlm.nih.gov/pubmed/28231835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0503-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi